NCT06198686View on ClinicalTrials.gov

An Evaluation of The Absolute Bioavailability of TH104

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 26, 2024

Primary Completion Date

February 11, 2024

Study Completion Date

November 6, 2024

Conditions
Healthy
Interventions
DRUG

Nalmefene

Opioid antagonist

Trial Locations (1)

89121

Novum Pharmaceutical Research Services, Las Vegas

All Listed Sponsors
lead

Tharimmune Inc

INDUSTRY

NCT06198686 - An Evaluation of The Absolute Bioavailability of TH104 | Biotech Hunter | Biotech Hunter